UCB has introduced new administration options for BIMZELX with a 320 mg dose available in a single-injection format, offered as a 2 mL prefilled syringe and autoinjector. These complement the existing 1 mL device format, which contains 160 mg of BIMZELX. This development provides patients needing a 320 mg dose with a streamlined single-injection choice.
Camille Lee, Head of U.S. Immunology at UCB, commented: "By adding a single-injection regimen, we are broadening available options and improving the treatment experience for individuals suffering from moderate-to-severe plaque psoriasis, active psoriatic arthritis with concurrent moderate-to-severe plaque psoriasis, and moderate-to-severe hidradenitis suppurativa—now able to receive a 320 mg dose of BIMZELX more conveniently."
